Used as a key intermediate in the synthesis of immunomodulatory drugs, particularly in the development of cereblon E3 ligase modulators. It plays a critical role in targeted protein degradation therapies, including PROTACs (proteolysis-targeting chimeras), which are emerging as powerful tools for treating cancers and other diseases by selectively degrading disease-causing proteins. Its structure enables effective binding to cereblon, making it valuable in designing molecules with enhanced selectivity and potency in oncology research.